Recent Activity, page-18

It's my understanding that the diagnostic test is medicare rebated. The benefits of a diagnostic test are that it is specific, provides faster results (4-5hrs vs 4-5 days), and does not require a clinician looking down a microscope. I also believe medico-legal factors and competition amongst pathology labs will play a part in the uptake of this product. I am very encouraged by the sales volume of 40,000+ test, which is an indication that pathology labs/hospitals like this product. Bring on the golden staphylococcus test!!! as sales will grow exponentially in my opinion. Remember, this is not just about individual products, but a platform that will support a range of other tests in the pipeline, such as TB. The platform is fully automated and pathology labs do not need to purchase additional capital (many labs don't have the space for more machines anyway) as current path lab equipment can be used to complete the diagnostic testing, that takes only a few hours.

I am very very upbeat about this company as it is, in my opinion, remarkably undervalued (a $30m cap). I believe this company will disrupt current diagnostic testing methods because it is cheaper and more efficient. It requires a strong management team to execute the business plan, which I believe it has.

I am not medically trained and these are my opinions only.